FDA Recall D-0183-2023
Glaxosmithkline Consumer Healthcare Holdings DBA Haleon · Warren, NJ
Class I — life-threatening Terminated 447 days on record
Highest impact — Class I recall — FDA determination of strong likelihood of serious adverse health consequence or death.
Product
Advil Liqui Gels (minis), Solubilized ibuprofen capsules, 200mg, Pain Reliever Fever Reducer (NSAID), 200 liquid filled capsules, Pfizer, Madison, NJ 07940, UPC 3 0573 1769 13 5
Reason for recall
Labeling: Illegible Label; the adhesive migrated onto a portion of the label, causing it to tear when peeled back
Recall record
- Recall number
D-0183-2023- Classification
- Class I
- Status
- Terminated
- Voluntary or mandated
- Voluntary: Firm initiated
- Firm notification
- Letter
- Distribution
- Nationwide in the USA.
- Recall initiated
- 2022-12-06
- Classified by FDA Center
- 2023-01-25
- FDA published
- 2023-02-01
- Terminated
- 2024-02-26
- Recalling firm
- Glaxosmithkline Consumer Healthcare Holdings DBA Haleon
- Firm location
- Warren, NJ